Oxford, UK,21 October 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today announced that it has appointed James Noble to join its Board as Non-Executive Director. James Noble MA FCA has held a number of high-profile positions in his long and successful career in the Biotech sector, most recently as Co-Founder and CEO of Adaptimmune Therapeutics. He was also the founding CEO of Immunocore Ltd. James currently serves as a non-executive director of Adaptimmune and is Deputy Chairman of NASDAQ-listed GW Pharmaceuticals.
Prior to that, James held a wide range of non-executive roles, including on the Boards of Medigene, Powderject and Oxford Glycosciences. He was previously CFO at British Biotech, where he took the company public in London and on NASDAQ and was formerly a director at the investment bank, Kleinwort Benson. James has extensive experience of both private and public sector markets.
James joins Celleron Therapeutics at an extremely exciting time for the Company and his knowledge and experience of both the Financial and Biotech Communities will be an invaluable asset as Celleron continues to develop its product portfolio and clinical trial programme, at the same time, extending its global reach into both China and the US.
Professor Nick La Thangue, CEO and Co-Founder of Celleron Therapeutics
“James is a welcome addition to Celleron’s Board. He is a very well respected and accomplished entrepreneur in the biopharma sector; and brings a wealth of experience to our Board. We are excited about working with James in driving our Company forward”
James Noble, commented:
“I am very excited to be joining the Celleron team. The company already has encouraging patient data and is planning the next stage in its development. I hope to be able to contribute towards building the company and its team”.
About Celleron Therapeutics
Celleron Therapeutics is a biopharma advancing a clinical and pre-clinical pipeline of precision therapies for different cancer indications. The company is a spin-out from Oxford University and located on the Oxford Science Park, UK. Celleron Therapeutics has built a proprietary platform around epigenetic control and immune modulation, providing its drugs with a two-pronged attack on cancer. Celleron’s approach seeks to align the right drug with the right patient enabling a personalised approach to cancer therapy.
Celleron Therapeutics’ focus is on those cancers where there is still an unmet need for long-term disease control. It is hoped that not only will patients volunteering for our clinical trials benefit directly, but the results from these studies will ultimately allow the general use of more effective, safer medicines. Our goal is not only to treat cancer but improve quality of life during therapy by reduction of side effects.
Celleron has a global license partnership with Astra Zeneca and is also initiating new trials in China. The company secured investment in 2016 from a consortium of South Korean investors. For more information see www.cellerontherapeutics.com
PDF Press release can be downloaded here